a
<We_can_help/>

What are you looking for?

Image Alt

2026 Edition

The Antibody Series 2026

The 6th edition of The Antibody Series took place in Évora, Portugal. The 2026 scientific agenda was chaired by Laura Walker and John Desjarlais and included special Keynotes and themes such as Lessons from Natural Antibody Repertoires, Harnessing Multispecificity to Drive Novel Functions, Computational Antibody Design, Emerging Antibody Based Therapies in Autoimmune Diseases and Engineering Agonism.

The Antibody Series 2026

Gallery

2026 Speakers

Associate Professor (since 2018) at ETH Zurich in the Department of Biosystems Science and Engineeri

Sarel Fleishman is a Professor at the Weizmann Institute of Science and Chief Scientist at Scala Bio

Dr Jo Viney,Ph.D. is co-founder, President and CEO of Seismic Therapeutic

Mark Cragg is Professor of Experimental Cancer Biology in the School of Cancer Sciences at the Unive

Surge Biswas is a co-founder the CEO at Nabla Bio

Dr. Lazar is Co-Founder and Chief Scientific Officer at Dualitas Therapeutics

George Georgiou is the Dula D. Cockrell Centennial Chair and Professor at UT Austin

Dr. Wyatt McDonnell is Co-Founder and CEO of Infinimmune, a preclinical antibody biotechnology comp

Anna Wec

Anna Wec is an Associate Director in Infectious Disease Research at Moderna, where she leads antibod

Robert Seder

Dr. Robert A. Seder is currently Acting Associate Director and Chief of the Cellular Immunology Sect

Co-founder and Executive Vice President of Technology and Scientific Office at FairJourney Bio

Kurt Jenkins, PhD is Senior Director of Biologics at Xilio Therapeutics, where he leads antibody discovery, in silico biologics, and protein sciences in support of the company's tumor-activated biologics pipeline

Senior Director of Biologics at Xilio Therapeutics, where he leads antibody discovery, in silico bio

Joanne Hulme

Melissa Geddie, Ph.D., is the SVP of Drug Discovery at Diagonal Therapeutics.

Joanne Hulme  Ph.D., currently is the Chief Scientific Officer of Radiant Biotherapeutics.

Aneesh Karatt-Vellatt, PhD

Aneesh Karatt-Vellatt, PhD is Chief Scientific Officer and Co-Founder at Maxion Therapeutics

Karyn O’Neil

Karyn O’Neil is the Chief Scientific Officer and Co-Founder at Aro Biotherapeutics

TAS 2026 highlights. Check our video!